



NEWS RELEASE

# Agenus to Provide Third Quarter 2023 Financial Report and Corporate Update

10/26/2023

LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its third quarter 2023 financial results via press release before the market opens on Tuesday, November 7, 2023.

## About Agenus

Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company's mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit [www.agenusbio.com](http://www.agenusbio.com) or [@agenus\\_bio](https://twitter.com/agenus_bio). Information that may be important to investors will be routinely posted on our website and social media channels.

## Investor

917-362-1370

[investors@agenusbio.com](mailto:investors@agenusbio.com)

## Media

781-674-4784

[communications@agenusbio.com](mailto:communications@agenusbio.com)

Source: Agenus Inc.